Business
Context Therapeutics® Reports Third Quarter 2022 Operating and Financial Results
Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial
About this update from Context Therapeutics Inc.
[{"type":"text","content":"Company reports preliminary ONA-XR data from two ongoing Phase 2 trials ONA-XR demonstrates preliminary 4-month PFS rate of 77.7% in ongoing Phase 2 trial evaluating the combination of ONA-XR and the antiestrogen anastrozole in PR+ recurrent endometrial cancer ONA-XR continues to exhibit favorable safety and tolerability profile Cash and cash equivalents of $39 million as of September 30, 2022, expected to provide runway into Q1 2024 PHILADELPHIA, Nov. 09, 2022 (GLOBE NEWSWIRE) -- Context Therapeutics Inc. (“Context” or the “Company”) (Nasdaq: CNTX), a women’s oncology company developing novel treatments for breast and gynecologic cancers, today reported on recent and upcoming business highlights and announced its financial results for the third quarter ended September 30, 2022. “We are pleased with the continued strengthening of onapristone extended release’s (“ONA-XR”) clinical profile. The preliminary Phase 2 findings for ONA-XR in combination with anastrozole in progesterone receptor-positive (PR+) recurrent endometrial cancer highlight a 4-month progression free survival (PFS) rate of 77.7%, and favorable safety and tolerability, representing a meaningful improvement over the single activity of either agent alone. Additionally, we are pleased to announce that we initiated the Phase 1b portion of our Phase 1b/2 ELONA breast cancer clinical trial to evaluate ONA-XR in combination with elacestrant. These achievements underscore our commitment to creating new standards of care in the women’s oncology field,” said Martin Lehr, CEO of Context Therapeutics. “Looking ahead, we plan to complete enrollment of the Phase 2 PR+ recurrent endometrial cancer trial and evaluate a potential registrational path. We will also continue to assess ONA-XR across multiple ongoing clinical trials, including an initial Phase 2 data readout in second- or third-line advanced or metastatic ER+,PR+,HER2- breast cancer in December 2022,” Lehr added. “Separately, we anticipate nominating a development candidate for our Claudin 6 bispecific antibody program in December. Our expected cash runway into Q1 2024 gives us the financial flexibility to execute on the advancement of our pipeline targeting female cancers.” ONA-XR Clinical Update PR+ Endometrial Cancer: In an ongoing Phase 2 trial in collaboration with Jefferson Health investigating ONA-XR 50mg BID i...